Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $925.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on REGN. StockNews.com upgraded Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a research note on Wednesday, March 13th. Royal Bank of Canada reiterated an outperform rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a research report on Tuesday, January 23rd. Finally, Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an outperform rating and a $1,125.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $970.57.

Regeneron Pharmaceuticals Trading Down 0.7 %

Regeneron Pharmaceuticals stock opened at $898.56 on Monday. The firm has a 50 day moving average of $956.81 and a 200 day moving average of $889.95. The firm has a market capitalization of $98.63 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the company posted $10.96 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals will post 38.18 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock worth $13,124,641 over the last quarter. Company insiders own 8.83% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Eudaimonia Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 11 shares during the last quarter. Ronald Blue Trust Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares during the period. Drive Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 12 shares in the last quarter. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Finally, LCM Capital Management Inc raised its position in Regeneron Pharmaceuticals by 2.5% during the fourth quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after acquiring an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.